Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 828 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma October 25, 2019 Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She... May 8, 2019 Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer March 28, 2019 Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... June 26, 2019 Load more HOT NEWS Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma... What if we count all that still remains?
